Larimar Therapeutics, Inc.(LRMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LRMR Larimar Therapeutics, Inc.

Market Closed 05-22 16:00:00 EDT

3.45

-0.12

-3.36%

盘后3.52

+0.07+2.03%

18:41 EDT

High3.66	Low3.43	Vol1.13M
Open3.60	D1 Closing3.57	Amplitude6.68%
Mkt Cap358.80M	Tradable Cap254.13M	Total Shares104.00M
T/O3.92M	T/O Rate1.53%	Tradable Shares73.66M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LRMR","market":"US","secType":"STK","nameCN":"Larimar Therapeutics, Inc.","latestPrice":3.45,"timestamp":1779480000000,"preClose":3.57,"halted":0,"volume":1126004,"hourTrading":{"tag":"盘后","latestPrice":3.52,"preClose":3.45,"latestTime":"18:41 EDT","volume":5703,"amount":19769,"timestamp":1779489718248,"change":0.07,"changeRate":0.02029,"amplitude":0.02029},"delay":0,"changeRate":-0.03361344537815117,"floatShares":73659546,"shares":104000000,"eps":-2.08756,"marketStatus":"Market Closed","change":-0.12,"latestTime":"05-22 16:00:00 EDT","open":3.6,"high":3.6635,"low":3.425,"amount":3920328.2931164,"amplitude":0.066807,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.08756,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1779782400000},"marketStatusCode":7,"adr":0,"listingDate":1403150400000,"exchange":"NASDAQ","adjPreClose":3.57,"preHourTrading":{"tag":"盘前","latestPrice":3.5579,"preClose":3.57,"latestTime":"09:22 EDT","volume":328,"amount":1151.826776,"timestamp":1779456165704,"change":-0.0121,"changeRate":-0.003389,"amplitude":0.069048},"postHourTrading":{"tag":"盘后","latestPrice":3.52,"preClose":3.45,"latestTime":"18:41 EDT","volume":5703,"amount":19769,"timestamp":1779489718248,"change":0.07,"changeRate":0.02029,"amplitude":0.02029},"volumeRatio":0.4980799808263924,"impliedVol":2.0878,"impliedVolPercentile":0.6135},"requestUrl":"/m/hq/s/LRMR","defaultTab":"news","newsList":[{"id":"2636268864","title":"Larimar Therapeutics shareholders approve increase in authorized common shares to 215 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2636268864","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636268864?lang=en_us&edition=fundamental","pubTime":"2026-05-20 04:30","pubTimestamp":1779222622,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics held its annual shareholder meeting on May 19, 2026.Shareholders backed an amendment to the company’s certificate of incorporation to raise authorized common stock to 215,000,000 shares from 115,000,000.Shareholders elected a one-year cadence for future advisory votes on executive pay, with the board set to hold those votes annually until the next required frequency vote.An adjournment authority was approved as a contingency to secure enough votes for the share authorization increase, though no adjournment was needed because the amendment passed at the meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Larimar Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Elec","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL23h2S5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635089531","title":"Exploring US High Growth Tech Stocks This May 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635089531","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635089531?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:08","pubTimestamp":1778843301,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the United States market has risen by 1.1% and is up 27% over the past year, with earnings forecasted to grow by 17% annually. In this favorable environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to leverage these promising conditions.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/software/nasdaq-clbt/cellebrite-di/news/exploring-us-high-growth-tech-stocks-this-may-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/software/nasdaq-clbt/cellebrite-di/news/exploring-us-high-growth-tech-stocks-this-may-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4535","FA","BK4613","BK4023","BK4130","CLBT","BK4139","BK4539","KARO","LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635719787","title":"Larimar Therapeutics Q1 net loss widens slightly R&D expenses fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2635719787","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635719787?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:08","pubTimestamp":1778756925,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics Q1 net loss widens slightly R&D expenses fallOverviewUS rare disease biotech reported Q1 net loss and lower R&D expenses yr/yrCompany advancing nomlabofusp toward rolling BLA subm","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL1N41R0GK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635719501","title":"BRIEF-Larimar Therapeutics Q1 Net Income USD -29.613 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635719501","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635719501?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:00","pubTimestamp":1778756448,"startTime":"0","endTime":"0","summary":"BRIEF-Larimar Therapeutics Q1 Net Income USD -29.613 Million\n\n\nMay 14 (Reuters) - Larimar Therapeutics Q1 income from operations USD -31.117 million.\n\nQ1 operating expenses USD 31.117 million\nQ1 EPS USD -0.31","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nPLXA1B115:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LRMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635584719","title":"Larimar Therapeutics Q1 EPS USD -0.31","url":"https://stock-news.laohu8.com/highlight/detail?id=2635584719","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635584719?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:00","pubTimestamp":1778756403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nPLXA1B115:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LRMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635571934","title":"Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635571934","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635571934?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:00","pubTimestamp":1778756403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA10G4WP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LRMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633924828","title":"Top News Today: Stocks Rise, Oil Falls, as War Restart Fears Subside","url":"https://stock-news.laohu8.com/highlight/detail?id=2633924828","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633924828?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:34","pubTimestamp":1778013240,"startTime":"0","endTime":"0","summary":"STOCKS: U.S. stocks rose and the Nasdaq and S&P 500 hit a new record highson strong earnings and as the U.S. downplayed tensions in the Middle East.TREASURYS: Treasury yields fell as inflation fears subsided.COMMODITIES: Oil futures fell after U.S. officials said Iranian strikes didn't mark the end of the cease-fire as the U.S. carries out an operation to help get vessels though the Strait of Hormuz.Anthropic is releasing new AI agents tailored to banks and other financial services businesses-part of the artificial intelligence company's plan to expand its reach among enterprise customers as it charts a path to an anticipated initial public offering as early as this year.Under the SEC's proposed amendments, public companies could choose to file one semiannual report and one annual report for each fiscal year in lieu of three quarterly reports and one annual report. The proposal is subject to a public comment period of 60 days, the SEC said, after which the regulator will vote on it.The","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CART","JJSF","BCRX","SGXZ57979304.SGD","KHC","MDGL","CRI","EXC","LU0058720904.USD","IHT","FAST","HNI","LU1059921491.USD","LU1699723380.USD","ASTE","LU0205194284.USD","FRPT","AROC","DLX","IE00BZ18W340.USD","LRMR","ITT","LU0266013472.USD","LU1642822529.SGD","LU2404859741.USD","LU2065732104.USD","MAR","LU0061475181.USD","IE00BD0PCF45.HKD","CLH","BK4196","BVS","LFUS","PFE","BK4534","LU0029874061.USD","GPN","LINE","LU0054578231.USD","LU0106831901.USD","LU1923622614.USD","INMD","LU0444971666.USD","BK4535","BK4179","CVS","SG9999001176.USD","BK4559","LPX","APO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632669902","title":"Larimar study backs skin frataxin as surrogate endpoint for nomlabofusp trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2632669902","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632669902?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:31","pubTimestamp":1777581082,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics published cross-species preclinical findings plus clinical patient data supporting skin sampling as a surrogate to track frataxin changes for its Friedreich’s ataxia drug candidate, nomlabofusp.Results have already been presented via online publication in Clinical and Translational Science.Study showed nomlabofusp raised frataxin in disease-relevant organs, with changes tracking levels measured in more accessible tissues such as skin or buccal cells.Data package has been reviewed by FDA to support potential use of skin frataxin as a reasonably likely surrogate endpoint for a registrational program under accelerated approval.Larimar reiterated plans to submit a Biologics License Application in June 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL5QSQyH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00BN0W2T93.GBP","SG9999014013.SGD","BK4588","SG9999014021.USD","BK4585","IE00BKPKM429.USD","BK4112","LRMR","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BN0W2W23.USD","LU2095319765.USD","IE00B3QW5Z07.USD","NDAQ","LU2210149790.SGD","IE00BN0W2V16.EUR","SG9999014039.USD","SG9999014005.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629844585","title":"Larimar Therapeutics Inc  expected to post a loss of 54 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2629844585","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629844585?lang=en_us&edition=fundamental","pubTime":"2026-04-24 21:06","pubTimestamp":1777035970,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics Inc  expected to post a loss of54cents a share - Earnings Preview Larimar Therapeutics Inc LRMR.OQ LRMR.O is expected to  show no change in quarterly revenue when it reports  resu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nL8N4171KD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626110719","title":"Larimar Therapeutics announces annual stockholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2626110719","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626110719?lang=en_us&edition=fundamental","pubTime":"2026-04-11 04:13","pubTimestamp":1775851983,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics scheduled 2026 annual meeting of stockholders for May 19, 2026, to be held virtually.Shareholders will vote on election of three Class III directors for terms expiring at 2029 annual meeting.Meeting agenda includes advisory vote on executive compensation, plus advisory vote on preferred frequency of future say-on-pay votes.Stockholders will also vote on charter amendment to raise authorized common shares to 215,000,000 from 115,000,000, plus proposal to adjourn meeting if needed to secure votes for that share increase.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Larimar Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrie","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL9LRGjf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LRMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624130795","title":"Nomlabofusp’s Manageable Risk, Strong Efficacy Signals, and Significant FA Market Upside Underpin Buy Rating on LRMR","url":"https://stock-news.laohu8.com/highlight/detail?id=2624130795","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624130795?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:15","pubTimestamp":1775045728,"startTime":"0","endTime":"0","summary":"Analyst Francois Brisebois from LifeSci Capital maintained a Buy rating on Larimar Therapeutics and keeping the price target at $25.00. Francois Br...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/nomlabofusps-manageable-risk-strong-efficacy-signals-and-significant-fa-market-upside-underpin-buy-rating-on-lrmr-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/nomlabofusps-manageable-risk-strong-efficacy-signals-and-significant-fa-market-upside-underpin-buy-rating-on-lrmr-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FA","LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621709185","title":"Larimar Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2621709185","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621709185?lang=en_us&edition=fundamental","pubTime":"2026-03-23 21:31","pubTimestamp":1774272698,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryLarimar Therapeutics Inc LRMR.OQ reported a quarterly adjusted loss of 73 cents per share for the quarter e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nL8N40B1D3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LRMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620366327","title":"Larimar Therapeutics Inc  expected to post a loss of 52 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2620366327","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620366327?lang=en_us&edition=fundamental","pubTime":"2026-03-20 20:41","pubTimestamp":1774010466,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics Inc  expected to post a loss of52cents a share - Earnings Preview Larimar Therapeutics Inc LRMR.OQ LRMR.O is expected to  show no change in quarterly revenue when it reports  resu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nL8N40815S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LRMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620778034","title":"Citi Reaffirms Their Buy Rating on Larimar Therapeutics (LRMR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620778034","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620778034?lang=en_us&edition=fundamental","pubTime":"2026-03-20 18:57","pubTimestamp":1774004237,"startTime":"0","endTime":"0","summary":"Citi analyst Samantha Semenkow reiterated a Buy rating on Larimar Therapeutics today and set a price target of $14.00. Semenkow covers the Healthca...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/citi-reaffirms-their-buy-rating-on-larimar-therapeutics-lrmr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/citi-reaffirms-their-buy-rating-on-larimar-therapeutics-lrmr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620244623","title":"Larimar Therapeutics Q4 net loss rises more than doubled to USD 62.5 million as R&D expenses jump more than doubled to USD 59.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620244623","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620244623?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:05","pubTimestamp":1773918311,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics Q4 net loss rises more than doubled to USD 62.5 million as R&D expenses jump more than doubled to USD 59.4 million. Larimar published a fourth-quarter and full-year 2025 financial results press release.Q4 net loss widened 117% to USD 62.5 million, while R&D expense rose 122% to USD 59.37 million, driven mainly by higher nomlabofusp manufacturing costs tied to process performance qualification and commercialization scale-up.For FY 2025, net loss increased 106% to USD 165.67 million and R&D expense rose 110% to USD 154.22 million, primarily reflecting higher nomlabofusp manufacturing costs and increased clinical, quality, and regulatory activity.Cash, cash equivalents and marketable securities totaled USD 136.9 million at year-end, and pro forma cash, cash equivalents and marketable securities were USD 244.5 million following USD 107.6 million in net proceeds from a February 2026 public offering.Nomlabofusp updates included FDA Breakthrough Therapy Designation, topli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL4vJpDm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","NDAQ","IE00BN0W2W23.USD","LRMR","BK4585","SG9999014039.USD","BK4139","IE00BGHQF748.EUR","LU2210149790.SGD","SG9999014005.SGD","BK4112","LU0314104364.USD","LU2210150020.SGD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","SG9999014021.USD","LU2095319765.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620424101","title":"BRIEF-Larimar Therapeutics Q4 Net Income USD -62.498 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620424101","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620424101?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:00","pubTimestamp":1773918048,"startTime":"0","endTime":"0","summary":"BRIEF-Larimar Therapeutics Q4 Net Income USD -62.498 Million\n\n\nMar 19 (Reuters) - Larimar Therapeutics Q4 income from operations USD -64.018 million.\n\nQ4 operating expenses USD 64.018 million\nQ4 EPS USD -0.73","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nPLX9116CD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LRMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620410012","title":"Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2620410012","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620410012?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:00","pubTimestamp":1773918004,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nTUACGLSBH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LRMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620958244","title":"Larimar Therapeutics Inc - Bla Submission Planned for June 2026; U.S. Launch Targeted First-Half 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2620958244","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620958244?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:00","pubTimestamp":1773918003,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nPLX9116CD:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LRMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620244864","title":"Larimar Therapeutics Q4 EPS USD -0.73","url":"https://stock-news.laohu8.com/highlight/detail?id=2620244864","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620244864?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:00","pubTimestamp":1773918003,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nPLX9116CD:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LRMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620244810","title":"Larimar Therapeutics Q4 Operating Expenses USD 64.018 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620244810","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620244810?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:00","pubTimestamp":1773918003,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nPLX9116CD:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LRMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.larimartx.com","stockEarnings":[{"period":"1week","weight":-0.0363},{"period":"1month","weight":-0.2434},{"period":"3month","weight":0.1616},{"period":"6month","weight":-0.0309},{"period":"1year","weight":0.7876},{"period":"ytd","weight":-0.0945}],"compareEarnings":[{"period":"1week","weight":0.0088},{"period":"1month","weight":0.0484},{"period":"3month","weight":0.0815},{"period":"6month","weight":0.1314},{"period":"1year","weight":0.2788},{"period":"ytd","weight":0.0934}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.583333,"avgChangeRate":0.088036},{"month":2,"riseRate":0.583333,"avgChangeRate":0.090114},{"month":3,"riseRate":0.25,"avgChangeRate":-0.145723},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.03405},{"month":5,"riseRate":0.416667,"avgChangeRate":-0.096797},{"month":6,"riseRate":0.545455,"avgChangeRate":0.006336},{"month":7,"riseRate":0.5,"avgChangeRate":-0.021968},{"month":8,"riseRate":0.5,"avgChangeRate":0.081374},{"month":9,"riseRate":0.416667,"avgChangeRate":0.000938},{"month":10,"riseRate":0.666667,"avgChangeRate":-0.029427},{"month":11,"riseRate":0.583333,"avgChangeRate":0.038429},{"month":12,"riseRate":0.583333,"avgChangeRate":0.050649}],"exchange":"NASDAQ","name":"Larimar Therapeutics, Inc.","nameEN":"Larimar Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Larimar Therapeutics, Inc.(LRMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Larimar Therapeutics, Inc.(LRMR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Larimar Therapeutics, Inc.,LRMR,Larimar Therapeutics, Inc.股票,Larimar Therapeutics, Inc.股票老虎,Larimar Therapeutics, Inc.股票老虎国际,Larimar Therapeutics, Inc.行情,Larimar Therapeutics, Inc.股票行情,Larimar Therapeutics, Inc.股价,Larimar Therapeutics, Inc.股市,Larimar Therapeutics, Inc.股票价格,Larimar Therapeutics, Inc.股票交易,Larimar Therapeutics, Inc.股票购买,Larimar Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Larimar Therapeutics, Inc.(LRMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Larimar Therapeutics, Inc.(LRMR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}